journal article·2026-08Open access

Nanoceria–curcumin nanoplatform enhances radiotherapy efficacy in triple-negative breast cancer via microenvironmental redox modulation and TNF-α–NF-κB/inflammatory program suppression

Longqing Hu, Zhongyuan Yin, Songwei Tan, Yu Deng, Xincai Qu, Ting Hu, Qiong Wang

Abstract

Triple-negative breast cancer (TNBC) derives only limited clinical benefit from radiotherapy (RT), partly due to abnormalities in the tumor microenvironment and dysregulated signaling pathways. By integrating TNBC cases from the METABRIC and TCGA cohorts, we implemented an analysis framework centered on RT-by-gene interaction terms, implicating TNF-α–NF-κB signaling and inflammatory response as potential effect modifiers of RT benefit. Based on a pathway-guided polyphenol–gene interaction screen, curcumin (Cur) was prioritized as a modulator of TNF-α–NF-κB/inflammation-related programs. We then engineered a multifunctional nanoplatform (TCC) that couples catalytic modulation of the tumor microenvironment with suppression of adaptive pro-survival programs. TCC was built on pH-responsive nanoceria (CeO 2 nanozymes) to modulate redox homeostasis and alleviate hypoxia, loaded with Cur, and coated with D-α-tocopherol polyethylene glycol succinate (TPGS) to improve stability and cellular uptake; cRGD was further introduced to generate cRGD-TCC for enhanced tumor targeting. In vitro and in vivo, TCC promoted G 2 /M-phase arrest, amplified RT-induced reactive oxygen species generation and DNA damage, and attenuated TNF-α–NF-κB/inflammatory programs and markers of inflammation, survival, and invasion. Collectively, TCC provides an integrated radiosensitization strategy that addresses microenvironmental barriers and adaptive tumor signaling, thereby potentially enhancing RT response in TNBC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Curcumin's Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (59)

Show source-provided references
1. Breast cancer heterogeneity and its implication in personalized precision therapy10.1186/s40164-022-00363-1 ↗
2. Breast cancer subtypes: response to radiotherapy and potential radiosensitisation10.1259/bjr.20120601 ↗
3. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish breast cancer cooperative group10.1200/JCO.2007.14.5565 ↗
4. Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study10.1186/s13058-023-01747-9 ↗
5. DNA damage checkpoint control in cells exposed to ionizing radiation10.1038/sj.onc.1206682 ↗
6. Ionizing-radiation induced DNA double-strand breaks: a direct and indirect lighting up10.1016/j.radonc.2013.06.013 ↗
7. Molecular mechanisms of tumor resistance to radiotherapy10.1186/s12943-023-01801-2 ↗
8. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response10.1016/j.molcel.2017.05.015 ↗
9. Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling10.1038/35104560 ↗
10. Radiation-induced signaling pathways that promote cancer cell survival10.3892/ijo.2014.2614 ↗
11. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy10.1259/0007-1285-26-312-638 ↗
12. Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression10.1016/j.ctrv.2006.05.003 ↗
13. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions10.1038/s41392-023-01332-8 ↗
14. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia10.1016/j.canlet.2012.11.019 ↗
15. Radiosensitization by the ATR inhibitor AZD6738 through generation of acentric micronuclei10.1158/1535-7163.MCT-16-0239 ↗
16. Targeting the ATM kinase to enhance the efficacy of radiotherapy and outcomes for cancer patients10.1016/j.semradonc.2021.09.008 ↗
17. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair10.1158/0008-5472.CAN-09-3573 ↗
18. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies10.18632/oncotarget.19079 ↗
19. Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance
20. Bidirectional regulation of reactive oxygen species for radiosensitization in nasopharyngeal carcinoma10.1186/s12951-025-03177-5 ↗
21. Tumor oxygenation and cancer therapy-then and now
22. Oxidative cell death in cancer: mechanisms and therapeutic opportunities10.1038/s41419-024-06939-5 ↗
23. Gold nanoparticles for applications in cancer radiotherapy: mechanisms and recent advancements10.1016/j.addr.2015.12.012 ↗
24. Hybrid manganese dioxide nanoparticles potentiate radiation therapy by modulating tumor hypoxia10.1158/0008-5472.CAN-15-3475 ↗
25. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles10.1038/nnano.2007.260 ↗
26. The role of cerium redox state in the SOD mimetic activity of nanoceria10.1016/j.biomaterials.2008.03.014 ↗
27. Bacterial membrane-modified cerium oxide nanoboosters enhance systemic antitumor effects of radiotherapy in metastatic triple-negative breast cancer10.1186/s12951-025-03187-3 ↗
28. Alleviating the hypoxic tumor microenvironment with MnO2-coated CeO2 nanoplatform for magnetic resonance imaging guided radiotherapy10.1186/s12951-023-01850-1 ↗
29. Multifunctional graphdiyne-cerium oxide nanozymes facilitate microRNA delivery and attenuate tumor hypoxia for highly efficient radiotherapy of esophageal cancer
30. Polyphenols: antioxidants and beyond10.1093/ajcn/81.1.215S ↗
31. Oxidative stress and inflammation: what polyphenols can do for us?10.1155/2016/7432797 ↗
32. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy10.1101/gad.186965.112 ↗
33. Negative feedback and adaptive resistance to the targeted therapy of cancer10.1158/2159-8290.CD-12-0018 ↗
34. Polyphenolic phytochemicals in cancer prevention and therapy: bioavailability versus bioefficacy10.1021/acs.jmedchem.6b01026 ↗
35. Advancing cancer radiotherapy: harnessing radiosensitizers and nanotechnology for enhanced tumor control
36. Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB, cyclinD and MMP-1 transcription10.1016/j.phymed.2009.04.008 ↗
37. Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer10.1186/s12951-023-01854-x ↗
38. Recent advances of D-alpha-tocopherol polyethylene glycol 1000 succinate based stimuli-responsive nanomedicine for cancer treatment10.1007/s11596-020-2185-1 ↗
39. Engineered lipid hybrid nanoparticles for targeted delivery of SH2 superbinder and breast cancer therapy10.1186/s12951-026-04249-w ↗
40. Nanoceria-curcumin conjugate: synthesis and selective cytotoxicity against cancer cells under oxidative stress conditions10.1016/j.jphotobiol.2020.111921 ↗
41. Asymmetric, amphiphilic RGD conjugated phthalocyanine for targeted photodynamic therapy of triple negative breast cancer10.1038/s41392-022-00906-2 ↗
42. The enzyme-like catalytic activity of cerium oxide nanoparticles and its dependency on Ce(3+) surface area concentration10.1039/C8NR00325D ↗
43. Nanoceria: an innovative strategy for cancer treatment10.1007/s00018-023-04694-y ↗
44. Redox active cerium oxide nanoparticles: current status and burning issues10.1002/smll.202102342 ↗
45. Morphology- and pH-dependent peroxidase mimetic activity of nanoceria10.1039/C8RA00622A ↗
46. Metal-phenolic network composites: from fundamentals to applications10.1039/D3CS00273J ↗
47. CD44 targeting biocompatible and biodegradable hyaluronic acid cross-linked zein nanogels for curcumin delivery to cancer cells: in vitro and in vivo evaluation10.1016/j.jconrel.2018.04.050 ↗
48. 99mTc radiolabeled HA/TPGS-based curcumin-loaded nanoparticle for breast cancer synergistic theranostics: design, in vitro and in vivo evaluation10.2147/IJN.S242490 ↗
49. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling10.1002/ijc.20333 ↗
50. Curcumin effectively inhibits oncogenic NF-kappaB signaling and restrains stemness features in liver cancer10.1016/j.jhep.2015.04.018 ↗
51. Curcumin inhibits LPS-induced EMT through downregulation of NF-κB-Snail signaling in breast cancer cells10.3892/or.2012.2080 ↗
52. Nanocarriers based on vitamin E-TPGS: design principle and molecular insights into improving the efficacy of anticancer drugs10.1016/j.ijpharm.2020.120045 ↗
53. Vitamin E TPGS as a molecular biomaterial for drug delivery10.1016/j.biomaterials.2012.03.046 ↗
54. Surface decoration of solid lipid nanoparticles with cyclic RGD peptides for precision therapy in high-risk neuroblastoma
55. α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug10.1021/nn301148e ↗
56. Be active or not: the relative contribution of active and passive tumor targeting of nanomaterials10.7150/ntno.19380 ↗
57. Research progress of radiotherapy combined with immunotherapy for breast cancer: mechanism exploration and clinical translation
58. Curcumin and tumor immune-editing: resurrecting the immune system10.1186/s13008-015-0012-z ↗
59. Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice10.1002/tox.20704 ↗